Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
Strasbourg (France), February 6, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, confirms that, in accordance with the provisions of the Attractiveness Act (“Loi d’Attractivité” – French Law No. 2024-537 of June 13, 2024), its shares are eligible for inclusion in the PEA-PME investment scheme*. As a result, Transgene (TNG) shares can be included or retained within this savings plan, which is designed to support the financing of small and medium-sized enterprises (“Petite et Moyenne Entreprise”, PME) and intermediate-sized enterprises (“Entreprise de Taille Intermédiaire”, ETI), while benefiting from the same tax advantages as traditional “Plan d’Epargne en Actions” investment scheme (PEA).
Tax advantages offered by PEA-PME and PEA are only available to French residents.
*Shares of European companies with fewer than 5,000 employees and an annual revenue of less than €1.5 billion or total assets not exceeding €2 billion are eligible for the PEA-PME investment scheme.
***
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.
Additional information about Transgene is available at:
Follow us on social media: X (formerly Twitter): — LinkedIn:
Contacts
| Media: | Investors & Analysts: |
| Caroline Tosch | Lucie Larguier |
| Corporate and Scientific Communications Manager | Chief Financial Officer (CFO) |
| +33 (0)3 68 33 27 38 | Nadege Bartoli |
| Investor Relations Analyst and Financial Communications Officer | |
| MEDiSTRAVA | +33 (0)3 88 27 91 00/03 |
| Frazer Hall/Sylvie Berrebi | |
| + 44 (0)203 928 6900 | |
Disclaimer
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document, available on the AMF website (-france.org) or on Transgene’s website (). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Attachment
